{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:10:38Z","timestamp":1791612638229,"version":"4.3.4"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T00:00:00Z","timestamp":1602028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T00:00:00Z","timestamp":1602028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Membranous nephropathy (MN) is a common cause of nephrotic syndrome in adults. The disease is induced by antibodies, which are directed against the podocyte protein phospholipase A\n                    <jats:sub>2<\/jats:sub>\n                    receptor 1 (PLA\n                    <jats:sub>2<\/jats:sub>\n                    R1-ab) in 80% of cases. B cell depleting treatments, most notably rituximab, a chimeric CD20-antibody, are often effective for treatment of MN. However, in 35\u201340% of patients rituximab fails to induce remission of disease and relapses after rituximab-induced remission are frequent. Therefore, alternative treatment options are necessary. Over the past years optimized antibodies targeting CD20 were designed to overcome side effects or sensitization to the murine fractions of rituximab and potentially improve B cell depletion. Ocrelizumab is a humanized B cell depleting antibody, approved for treatment of multiple sclerosis (MS). Here, we report the case of a patient who was diagnosed with MS and, 8\u00a0years later, developed PLA\n                    <jats:sub>2<\/jats:sub>\n                    R1-associated MN. Treatment for MS was switched to the CD20-antibody ocrelizumab, which was expected to deplete B cells and potentially induce remission of MN. After treatment with ocrelizumab PLA\n                    <jats:sub>2<\/jats:sub>\n                    R1-ab disappeared from the circulation and the patient developed remission of proteinuria. Ocrelizumab might be an efficacious treatment alternative for patients with MN who fail to achieve remission or are immunologically sensitized to rituximab.\n                  <\/jats:p>","DOI":"10.1007\/s40620-020-00874-2","type":"journal-article","created":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T06:03:16Z","timestamp":1602050596000},"page":"603-606","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Successful treatment of PLA2R1-antibody positive membranous nephropathy with ocrelizumab"],"prefix":"10.1093","volume":"34","author":[{"given":"Tilman","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schulze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid","family":"Harendza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elion","family":"Hoxha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,10,7]]},"reference":[{"key":"874_CR1","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2215\/CJN.11761116","volume":"12","author":"WG Couser","year":"2017","unstructured":"Couser WG (2017) Primary membranous nephropathy. Clin J Am Soc Nephrol 12:983\u2013997. https:\/\/doi.org\/10.2215\/CJN.11761116","journal-title":"Clin J Am Soc Nephrol"},{"key":"874_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","volume":"361","author":"LH Beck","year":"2009","unstructured":"Beck LH, Bonegio RGB, Lambeau G et al (2009) M-type phospholipase A 2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361:11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa0810457","journal-title":"N Engl J Med"},{"key":"874_CR3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1056\/NEJM199307083290203","volume":"329","author":"A Schieppati","year":"1993","unstructured":"Schieppati A, Mosconi L, Perna A et al (1993) Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 329:85\u201389. https:\/\/doi.org\/10.1056\/NEJM199307083290203","journal-title":"N Engl J Med"},{"key":"874_CR4","doi-asserted-by":"publisher","first-page":"e0221293","DOI":"10.1371\/journal.pone.0221293","volume":"14","author":"M Mahmud","year":"2019","unstructured":"Mahmud M, Pinnschmidt HO, Reinhard L et al (2019) Role of phospholipase A2 receptor 1 antibody level at diagnosis for long-term renal outcome in membranous nephropathy. PLoS ONE 14:e0221293. https:\/\/doi.org\/10.1371\/journal.pone.0221293","journal-title":"PLoS ONE"},{"key":"874_CR5","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1681\/ASN.2009080861","volume":"21","author":"N Polanco","year":"2010","unstructured":"Polanco N, Guti\u00e9rrez E, Covars\u00ed A et al (2010) Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 21:697\u2013704. https:\/\/doi.org\/10.1681\/ASN.2009080861","journal-title":"J Am Soc Nephrol"},{"key":"874_CR6","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/ki.2012.209","volume":"82","author":"E Hoxha","year":"2012","unstructured":"Hoxha E, Knei\u00dfler U, Stege G et al (2012) Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int 82:797\u2013804. https:\/\/doi.org\/10.1038\/ki.2012.209","journal-title":"Kidney Int"},{"key":"874_CR7","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1056\/NEJMc1011678","volume":"364","author":"H Debiec","year":"2011","unstructured":"Debiec H, Ronco P (2011) PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl J Med 364:689\u2013690. https:\/\/doi.org\/10.1056\/NEJMc1011678","journal-title":"N Engl J Med"},{"key":"874_CR8","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1681\/ASN.2014070640","volume":"26","author":"P Ruggenenti","year":"2015","unstructured":"Ruggenenti P, Debiec H, Ruggiero B et al (2015) Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. J Am Soc Nephrol 26:2545\u20132558. https:\/\/doi.org\/10.1681\/ASN.2014070640","journal-title":"J Am Soc Nephrol"},{"key":"874_CR9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa1814427","volume":"381","author":"FC Fervenza","year":"2019","unstructured":"Fervenza FC, Appel GB, Barbour SJ et al (2019) Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med 381:36\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1814427","journal-title":"N Engl J Med"},{"key":"874_CR10","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1681\/ASN.2016091022","volume":"28","author":"JAJG van den Brand","year":"2017","unstructured":"van den Brand JAJG, Ruggenenti P, Chianca A et al (2017) Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy. J Am Soc Nephrol 28:2729\u20132737. https:\/\/doi.org\/10.1681\/ASN.2016091022","journal-title":"J Am Soc Nephrol"},{"key":"874_CR11","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1681\/ASN.2012020181","volume":"23","author":"P Ruggenenti","year":"2012","unstructured":"Ruggenenti P, Cravedi P, Chianca A et al (2012) Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol 23:1416\u20131425. https:\/\/doi.org\/10.1681\/ASN.2012020181","journal-title":"J Am Soc Nephrol"},{"key":"874_CR12","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.3389\/fimmu.2019.03069","volume":"10","author":"S Boyer-Suavet","year":"2020","unstructured":"Boyer-Suavet S, Andreani M, Lateb M et al (2020) Neutralizing anti-rituximab antibodies and relapse in membranous nephropathy treated with rituximab. Front Immunol 10:3069. https:\/\/doi.org\/10.3389\/fimmu.2019.03069","journal-title":"Front Immunol"},{"key":"874_CR13","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1046\/j.1365-2141.2001.03166.x","volume":"115","author":"LE van der Kolk","year":"2001","unstructured":"van der Kolk LE, Grillo-Lopez AJ, Baars JW et al (2001) Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 115:807\u2013811. https:\/\/doi.org\/10.1046\/j.1365-2141.2001.03166.x","journal-title":"Br J Haematol"},{"key":"874_CR14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G et al (2017) Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 376:221\u2013234. https:\/\/doi.org\/10.1056\/NEJMoa1601277","journal-title":"N Engl J Med"},{"key":"874_CR15","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1474-4422(08)70192-3","volume":"7","author":"D Franciotta","year":"2008","unstructured":"Franciotta D, Salvetti M, Lolli F et al (2008) B cells and multiple sclerosis. Lancet Neurol 7:852\u2013858. https:\/\/doi.org\/10.1016\/S1474-4422(08)70192-3","journal-title":"Lancet Neurol"},{"key":"874_CR16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.cca.2013.03.015","volume":"421","author":"C D\u00e4hnrich","year":"2013","unstructured":"D\u00e4hnrich C, Komorowski L, Probst C et al (2013) Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy. Clin Chim Acta 421:213\u2013218. https:\/\/doi.org\/10.1016\/j.cca.2013.03.015","journal-title":"Clin Chim Acta"},{"key":"874_CR17","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2002-06-1639","volume":"101","author":"T Manshouri","year":"2003","unstructured":"Manshouri T, Do K, Wang X et al (2003) Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 101:2507\u20132513. https:\/\/doi.org\/10.1182\/blood-2002-06-1639","journal-title":"Blood"},{"key":"874_CR18","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1097\/01.cji.0000203081.43235.d7","volume":"29","author":"M-L Lefebvre","year":"2006","unstructured":"Lefebvre M-L, Krause SW, Salcedo M, Nardin A (2006) Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum. J Immunother 29:388\u2013397. https:\/\/doi.org\/10.1097\/01.cji.0000203081.43235.d7","journal-title":"J Immunother"},{"key":"874_CR19","doi-asserted-by":"publisher","first-page":"3900","DOI":"10.1182\/blood.V95.12.3900.012k14_3900_3908","volume":"95","author":"J Golay","year":"2000","unstructured":"Golay J, Zaffaroni L, Vaccari T et al (2000) Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95:3900\u20133908","journal-title":"Blood"},{"key":"874_CR20","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1634\/theoncologist.2008-0089","volume":"13","author":"X Zhou","year":"2008","unstructured":"Zhou X, Hu W, Qin X (2008) The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist 13:954\u2013966. https:\/\/doi.org\/10.1634\/theoncologist.2008-0089","journal-title":"Oncologist"},{"key":"874_CR21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4161\/mabs.22771","volume":"5","author":"C Klein","year":"2013","unstructured":"Klein C, Lammens A, Sch\u00e4fer W et al (2013) Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. mAbs 5:22\u201333. https:\/\/doi.org\/10.4161\/mabs.22771","journal-title":"mAbs"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-020-00874-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-020-00874-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-020-00874-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:55:07Z","timestamp":1777564507000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/34\/2\/603\/8325819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,7]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["874"],"URL":"https:\/\/doi.org\/10.1007\/s40620-020-00874-2","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,7]]},"assertion":[{"value":"20 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that the patient reported here has provided authorization for use of medical records for research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Article information"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}